Brief: FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness
08/07/2025 12:32
July 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O: FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESS BRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALS Source text: ID:nPn1qRJLpa Further company coverage: BCLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview